XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Last trade$1.79
Day change-$0.06 (-3.24%)
Day range$1.79 – $1.87
Volume41,777
Market cap$56M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$56.4M
Price / earnings
—
Price / book
0.45×
Price / sales
—
EV / sales
—
EV / EBITDA
1.05×
Profitability
Earnings per share
-$1.43
Return on assets
-33.89%
Return on equity
-35.13%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
39.51×
Quick ratio
39.51×
Cash ratio
39.02×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$41M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for XBIT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$663K
$850K
$1.07M
$4.4M
$967K
$1M
$1.93M
$927K
Research and development
$4.66M
$5.3M
$5.21M
$25.36M
$5.08M
$5.34M
$11.62M
$7.82M
Total operating expenses
$5.32M
$6.15M
$6.27M
$29.76M
$6.05M
$6.34M
$13.55M
$8.75M
Operating income
-$5.32M
-$6.15M
-$6.27M
-$29.76M
-$6.05M
-$6.34M
-$13.55M
-$8.75M
Interest expense
$0
$0
$0
$0
$0
$0
-$88K
$0
Income before taxes
-$4.43M
-$6.68M
-$5.46M
-$26.82M
-$5.91M
-$1.73M
-$10.86M
-$10.55M
Income taxes
$35K
$46K
$49K
$76K
$102K
$28K
$29K
-$41K
Net income
-$4.46M
-$6.73M
-$5.51M
-$26.89M
-$6.01M
-$1.76M
-$10.88M
-$10.51M
Net income attributable to common shareholders
-$4.46M
-$6.73M
-$5.51M
-$26.89M
-$6.01M
-$1.76M
-$10.88M
-$10.51M
EBITDA
-$5.07M
-$5.84M
-$5.94M
-$29.38M
-$5.62M
-$5.9M
-$13.11M
-$8.31M
Basic earnings per share
-$0.15
-$0.22
-$0.18
-$0.88
-$0.20
-$0.06
-$0.36
-$0.34
Diluted earnings per share
-$0.15
-$0.22
-$0.18
-$0.88
-$0.20
-$0.06
-$0.36
-$0.34
Recent news
Company coverage with links to the original publishers.
XBiotech Inc. (NASDAQ: XBIT) announced the appointment of Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy, who has been with the company for 17 years and served as interim CEO following the founder's retirement, will now share leadership responsibilities with Simard, who joined XBiotech in 2012 and has contributed to clinical trial development across multiple therapeutic areas.
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside Dr. Sushma Shivaswamy, effective October 23, 2026. Dr. Shivaswamy, who has been with the company for 17 years and served as Interim CEO since December 2025, will now share leadership responsibilities with Simard. The co-CEO structure aims to leverage their complementary skills and scientific expertise to advance the company's true Human antibody therapies across oncology, inflammatory diseases, and infectious diseases.
XBiotech announced positive Phase II results for its anti-IL-1α monoclonal antibody vilamakitug (Natrunix) in treating refractory metastatic colorectal cancer. The investigator-sponsored TASKIN trial met its primary efficacy endpoint with 61.3% 12-month overall survival in the treatment arm versus 55.7% in the control arm. Notably, exploratory analysis showed a statistically significant 62% reduction in death risk for right-sided colon tumors, a historically aggressive subtype with high unmet medical needs.
XBiotech announced positive final efficacy results from the Phase II TASKIN trial of its anti-IL-1α monoclonal antibody Vilamakitug (XB2001) combined with standard chemotherapy for refractory metastatic colorectal cancer. The study met its primary efficacy endpoint with a 12-month overall survival rate of 61.3% versus 55.7% in the control group. An exploratory subgroup analysis showed a statistically significant 62% reduction in mortality risk for patients with right-sided tumors.
XBiotech announced positive Phase II results from the TASKIN trial showing its anti-IL-1α monoclonal antibody vilamakitug (XB2001) met primary efficacy criteria with 61.3% 12-month overall survival in refractory metastatic colorectal cancer patients. An exploratory analysis revealed significant survival benefits in right-sided tumors, with a 62% reduction in death risk compared to control.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Jul 15, 2021
$2.0995
Jul 23, 2021
special
Stock splits
Historical share-structure events and their execution dates.